News

NewAmsterdam Pharma's Upcoming Investor Conference Highlights

NewAmsterdam Pharma's Upcoming Investor Conference Highlights

NewAmsterdam Pharma's Upcoming Investor Conference Schedule

NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS), a pioneering force in the biopharmaceutical landscape, is gearing up for an exciting lineup of investor conferences in June. Recognized for developing oral non-statin medicines aimed at significantly improving the lives of patients at risk for cardiovascular disease (CVD), NewAmsterdam continues to push forward with their mission even as they prepare for these crucial events. The company's innovative approach looks to meet the needs of individuals with elevated low-density lipoprotein cholesterol (LDL-C) who may not have found success with existing therapies.

Highlights of the Conferences

Company management is set to participate in several prestigious investor conferences, giving key stakeholders the opportunity to gain insights into their latest advancements. Here’s a brief overview of what’s to come:

William Blair 45th Annual Growth Stock Conference

Set to take place in Chicago, NewAmsterdam’s CEO, Michael Davidson, M.D., will present a corporate overview on Tuesday, June 3. Attendees can tune in at 3:20 p.m. CT to hear about the company's strategic vision and recent developments in their CVD-focused therapies.

Jefferies Global Healthcare Conference 2025

Following the William Blair event, NewAmsterdam will be at the Jefferies Global Healthcare Conference in New York on Wednesday, June 4. Chief Financial Officer, Ian Somaiya, is scheduled for an engaging fireside chat at 10:30 a.m. ET, where he will discuss the company's financial outlook and market position.

Goldman Sachs 46th Annual Healthcare Conference

Miami will be the location for the final event in this series, with Michael Davidson returning alongside Matthew Phillipe, Executive Vice President and Head of Investor Relations, for a fireside chat on Monday, June 9 at 2:40 p.m. ET. This discussion is anticipated to cover NewAmsterdam's innovative therapies and their potential impact on patients suffering from high LDL-C levels.

Live Webcasts and Access to Presentations

For those unable to attend in person, live webcasts of these vital presentations will be available through the investor relations section of the NewAmsterdam Pharma website. Post-event, archived replays will also be accessible, ensuring that stakeholders can stay informed about the company’s developments and insights shared during these conferences.

About NewAmsterdam Pharma

NewAmsterdam Pharma (Nasdaq: NAMS) stands at the forefront of biopharmaceutical innovation with a mission to enhance patient care within populations suffering from metabolic diseases. Their core focus is on delivering a safe and convenient LDL-lowering therapy. Their flagship product, obicetrapib, is currently under investigation in multiple phase 3 trials as a potent, oral therapy designed to complement statin treatments for patients with elevated LDL-C who are not responding to existing therapies.

Company Contact Information

For inquiries, the company is accessible as follows:

Matthew Philippe
P: 1-917-882-7512
Email: matthew.philippe@newamsterdampharma.com

Media Contact
Spectrum Science on behalf of NewAmsterdam
Jaryd Leady
P: 1-856-803-7855
Email: jleady@spectrumscience.com

Investor Contact
Precision AQ on behalf of NewAmsterdam
Austin Murtagh
P: 1-212-698-8696
Email: austin.murtagh@precisionaq.com

Frequently Asked Questions

What is NewAmsterdam Pharma known for?

NewAmsterdam Pharma specializes in developing innovative oral therapies for cardiovascular disease, particularly focusing on LDL-lowering treatments.

When are the upcoming investor conferences?

The conferences are scheduled for June 3, June 4, and June 9 of the upcoming month.

Who will represent the company at these conferences?

Key representatives include CEO Michael Davidson, M.D. and CFO Ian Somaiya, among other executives.

How can stakeholders access the conference presentations?

Live webcasts will be available via the NewAmsterdam Pharma investor relations website, with replays posted afterward.

What is the significance of obicetrapib?

Obicetrapib is a promising oral therapy under investigation that aims to provide a novel solution for lowering LDL-C in patients at risk for cardiovascular disease.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Ceva's Wireless IP Dominance Amid AI Device Surge

Updated Category News Views 99

Keeping the Wireless IP Crown Against All Odds Look, I've seen dominance play out in the markets over the years, but Ceva’s stranglehold on the wireless interface IP market is something fierce. They've got a whopping 68% market share, and folks, that’s 12 times their closest competitor. Talk about leaving the competition eating dust! For a field growing at a solid...

Continue Reading
Watches of Switzerland Dazzles with Holiday Campaign

Updated Category News Views 0

Swiss Timepieces Take Center Stage Ever feel like there's a certain art to gift-giving? Apparently, The Watches of Switzerland Group thinks so, and they're not holding back in showing us how it's done with their new 'Brilliantly Given' campaign. They’re taking a classic approach by spotlighting luxury timepieces and fine jewelry just in time for the holiday...

Continue Reading
Aosom Unveils Its Boldest Black Friday Extravaganza

Updated Category News Views 31

Black Friday Heat Kicks Off Early at Aosom All the seasoned shoppers out there smell a deal from a mile away, and Aosom isn't taking any chances by launching their Black Friday bash smack dab on November 2nd. This isn’t just any sale, it’s shaping up to be their most gigantic festival of discounts yet. Across Europe and North America, folks are rubbing their hands...

Continue Reading
Zensar Sees Solid Revenue Growth in Q2FY27

Updated Category News Views 54

Zensar's Q2 Performance: Growth Amid Shifting Sands Is Zensar Technologies quietly carving a spot for itself in the cutthroat tech marketplace, or are we just seeing a temporary glimmer during a complex market scenario? With a constant currency growth rate of 4.1% in Q2FY27, Zensar sure seems to have gotten something right. But does this mean they’ve got the long-term...

Continue Reading
German Court Backs Usmanov in Legal Standoff with EU

Updated Category News Views 71

Usmanov Scores a Win in German Courts The courtroom dramas play out yet again, and this time the spotlight's on Alisher Usmanov versus the European Union Council. It's a scene rich in bureaucratic fireworks, where Germany's Federal Court of Justice shined a beam of clarity amidst all that legal fog. They call it a 'landmark ruling'—a voice of reason brushing aside the...

Continue Reading
Envision's 800V DC System Cuts the Powercake First

Updated Category News Views 42

Envision Hits a Milestone in AI Power Dynamics You ever feel like the future is knocking on your door, but you've still got your headphones on? Well, Envision just kicked the door open with the world's first commercial deployment of an integrated 800-volt direct current (800V DC) power system in a large-scale AI data center. This technological marvel is now up and running...

Continue Reading
Atrium's Heart Therapies: ATR 1072's Promising Data

Updated Category News Views 60

Atrium Therapeutics Strikes a Chord with New Data Tuning into the heartbeats of breakthrough developments, Atrium Therapeutics dropped some fresh, nonclinical insights about their latest contender, ATR 1072. This wasn't just any ordinary announcement; it's like when the market hears whispers of a Fed rate adjustment. The venue? The American Heart Association's 2026...

Continue Reading
Why Renters Insurance is a Must for Tenants

Updated Category News Views 11

Diving Into Renters Insurance: What You Need to Know Renters insurance isn't just another unnecessary add-on; it's practically a necessity if you're renting. Joseph Puckett, of Golseth and Puckett Agency: Allstate Insurance, gives us the lowdown on the essential protection renters need but often overlook. The Myth and the Reality Ah, the age-old misconception—many...

Continue Reading
Immunic's November Moves: Conferences and Clinical Trials

Updated Category News Views 87

Immunic Taps Into November Conferences Every now and then, you catch a company that's not just spinning its wheels but making some potentially big waves in their field. This time, it's Immunic, Inc. (Nasdaq: IMUX), stepping into the spotlight. They're strutting their stuff at several investor conferences this November, starting with Boston and New York, then hopping over...

Continue Reading
Lectric Rolls Out Limited-Edition XP4 Ebike Upgrades

Updated Category News Views 51

Pedaling into a New Era of eBikes When the top contender in the American eBike world rolls out something new, you'd better believe it's worth a look. Lectric eBikes has just unwrapped three limited-edition versions of their beloved XP4, revealing a fresh take on a ride already admired by thousands. Let's dig into this new release. What's New with the XP4 This ain't just a...

Continue Reading

Top 5 Most Recently Viewed Articles

Frontera Energy and CGX Energy Update on Corentyne Block Issues

Updated Category News Views 152

Joint Venture's Update on Corentyne Block License Challenges Frontera Energy Corporation (TSX: FEC) and CGX Energy Inc. (TSXV: OYL) recently shared significant updates about their joint venture concerning the Corentyne block license. The project has encountered some challenges as the government of Guyana has communicated its stance on the continued status of the joint...

Continue Reading
Analysis of IT Salary Trends and Growth in North America

Updated Category News Views 315

Understanding the Latest Trends in IT Salaries The landscape for IT salaries in North America is evolving, revealing important insights about the current job market for IT professionals. Recent surveys have shown that while there are opportunities for growth, salaries have not kept pace with inflation, creating a complex environment for job seekers. The latest IT salary...

Continue Reading
Ellen Rose Joins Asurity Advisors as Senior Advisor

Updated Category News Views 470

Ellen Rose Joins Asurity Advisors as Senior Advisor Asurity Advisors™, a prominent name in regulatory risk and compliance consulting, is thrilled to announce the addition of Ellen Rose as a Senior Advisor. With an extensive background in mortgage banking spanning over 40 years, Ellen brings substantial expertise in both residential and commercial lending alongside a...

Continue Reading
NANO Nuclear Energy Secures Major Investment Boost of $60 Million

Updated Category News Views 202

NANO Nuclear Energy Announces $60 Million Private Placement NANO Nuclear Energy Inc. (NASDAQ: NNE), known for its pioneering advancements in nuclear energy technologies, has recently made headlines with the announcement of a private placement agreement expected to generate $60 million in gross proceeds. This significant funding boost is set to elevate the company's cash...

Continue Reading
Impact of the February 28 Spending Freeze on Major Retailers

Updated Category News Views 227

Understanding the February 28 Economic Boycott On February 28, Americans across the country are planning a one-day economic boycott, a clear statement against major retailers that are scaling back their diversity, equity, and inclusion initiatives as a response to recent political shifts. This boycott is organized by The People’s Union USA, targeting significant players...

Continue Reading